• Research & Development

  In PAH, Ventavis Shows Low Ability to Improve Survival Rates, Study Finds

  Posted by Pulmonary Hypertension News Moderator on November 7, 2018 at 2:24 pm

  Inhaled Ventavis (iloprost) shows little ability to improve the survival rate of PAH patients, despite clinical improvements, real-world data suggests. Read more about this here.

  What do you think about this news?

  Pulmonary Hypertension News Moderator replied 7 years, 4 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply